Incyte Corporation
Company & revenue
About Incyte Corporation
Who they are
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates.
Detailed revenue, brand and relationship research has not yet been completed for INCY.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
66
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
81
Strong
Financial Strength
64
Business Quality / Moat
96
Management
100
Growth Quality
69
Risk / Durability
77
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
79
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
76/100
Building Historical Record
Model Score 76/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as mixed to moderately strong.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Valuation scores attractively
- •Recent buyback activity is present
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for INCY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can INCY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is INCY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is INCY likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is INCY's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
66
Opportunity Score
79
Market Cap
$23.37B
P/E Ratio
14.9
EPS
$8.13
52-Week High
$132.60
52-Week Low
$82.82
Beta
0.77
Intrinsic Value
$310.40
Analyst Target
$130.00
Shares Outstanding
200.7M
Total Revenue
$5.82B
Total Debt
$38.3M
Dividend
No current dividend
Liquidation Value / Share
$31.61
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for INCY
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on INCY.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera.
- +Product opportunity: PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types.
- +Product opportunity: and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic l.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
64
Aug 14, 2026
Change
+2.3
points
Current Score
66
Oct 1, 2026
Category Changes
INCY increased 2.3 points because Valuation improved by 18.3 points.
Positive Contributors
- + Valuation improved by 18.3 points
Projected Score
Projected Score
73
Projected Change
+6.4%
Preliminary comparable-period financial changes suggest improvement of approximately 6.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$115.30
Intrinsic Value
$310.40
Difference
−$195.10
-62.9% vs IV
Margin of Safety
62.9%
Related Companies
BiotechnologyNews
INCY or TECH: Which Is the Better Value Stock Right Now?
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial